Targeting a specific pathway in cancer treatment
Targeting the FBXO44/SUV39H1 Pathway in Cancer
['FUNDING_R01'] · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · NIH-10993109
This study is looking at how blocking a specific pathway in cancer cells might help boost the immune system's ability to fight tumors, making them more vulnerable to treatments like immunotherapy, and it's designed for people with cancer who want to know more about new ways to improve their treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10993109 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the FBXO44/SUV39H1 pathway in cancer cells, focusing on how inhibiting this pathway can activate certain genetic elements that may enhance the immune response against tumors. By silencing repetitive elements in cancer cells, the study aims to induce stress that could make tumors more susceptible to existing cancer therapies, particularly immunotherapies. The approach involves advanced techniques like RNA interference to explore the effects of this pathway on tumor growth and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who may benefit from enhanced immunotherapy responses.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not respond to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by enhancing the immune system's ability to fight tumors.
How similar studies have performed: Other research has shown promising results in targeting similar pathways to enhance cancer treatment, suggesting that this approach could be effective.
Where this research is happening
LA JOLLA, UNITED STATES
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPRUCK, CHARLES H. — SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- Study coordinator: SPRUCK, CHARLES H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy